Cargando…
Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
There are limited data on cardiovascular efficacy and safety of type 2 diabetes therapies in Japan, where treatments are characterized by lower metformin use and higher dipeptidyl peptidase‐4 inhibitor (DPP4i) use versus other countries. We investigated the cardiovascular outcomes in Japanese patien...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779275/ https://www.ncbi.nlm.nih.gov/pubmed/32530554 http://dx.doi.org/10.1111/jdi.13321 |
_version_ | 1783631299852894208 |
---|---|
author | Kohsaka, Shun Takeda, Masayoshi Bodegård, Johan Thuresson, Marcus Kosiborod, Mikhail Yajima, Toshitaka Wittbrodt, Eric Fenici, Peter |
author_facet | Kohsaka, Shun Takeda, Masayoshi Bodegård, Johan Thuresson, Marcus Kosiborod, Mikhail Yajima, Toshitaka Wittbrodt, Eric Fenici, Peter |
author_sort | Kohsaka, Shun |
collection | PubMed |
description | There are limited data on cardiovascular efficacy and safety of type 2 diabetes therapies in Japan, where treatments are characterized by lower metformin use and higher dipeptidyl peptidase‐4 inhibitor (DPP4i) use versus other countries. We investigated the cardiovascular outcomes in Japanese patients with type 2 diabetes initiating sodium–glucose cotransporter 2 inhibitors (SGLT2i) matched 1:1 to patients initiating other glucose‐lowering drugs (33,890 patients/group) or DPP4i (9,876 patients/group). SGLT2i initiation was associated with lower risks (hazard ratio of in‐hospital death [death] 0.56, 95% confidence interval [CI] 0.47–0.67; hospitalization for heart failure 0.75, 95% CI 0.64–0.89; composite of hospitalization for heart failure or death 0.65, 95% CI 0.58–0.74 and stroke 0.66, 95% CI 0.52–0.84 versus other glucose‐lowering drugs and lower risks of death 0.52, 95% CI 0.36–0.73) and composite of hospitalization for heart failure or death (0.65, 95% CI 0.51–0.83) versus DPP4i. In conclusion, SGLT2i initiators had lower risks of cardiovascular events versus other glucose‐lowering drug initiators and, uniquely, versus DPP4i initiators in Japanese real‐world practice. |
format | Online Article Text |
id | pubmed-7779275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77792752021-01-08 Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study Kohsaka, Shun Takeda, Masayoshi Bodegård, Johan Thuresson, Marcus Kosiborod, Mikhail Yajima, Toshitaka Wittbrodt, Eric Fenici, Peter J Diabetes Investig Articles There are limited data on cardiovascular efficacy and safety of type 2 diabetes therapies in Japan, where treatments are characterized by lower metformin use and higher dipeptidyl peptidase‐4 inhibitor (DPP4i) use versus other countries. We investigated the cardiovascular outcomes in Japanese patients with type 2 diabetes initiating sodium–glucose cotransporter 2 inhibitors (SGLT2i) matched 1:1 to patients initiating other glucose‐lowering drugs (33,890 patients/group) or DPP4i (9,876 patients/group). SGLT2i initiation was associated with lower risks (hazard ratio of in‐hospital death [death] 0.56, 95% confidence interval [CI] 0.47–0.67; hospitalization for heart failure 0.75, 95% CI 0.64–0.89; composite of hospitalization for heart failure or death 0.65, 95% CI 0.58–0.74 and stroke 0.66, 95% CI 0.52–0.84 versus other glucose‐lowering drugs and lower risks of death 0.52, 95% CI 0.36–0.73) and composite of hospitalization for heart failure or death (0.65, 95% CI 0.51–0.83) versus DPP4i. In conclusion, SGLT2i initiators had lower risks of cardiovascular events versus other glucose‐lowering drug initiators and, uniquely, versus DPP4i initiators in Japanese real‐world practice. John Wiley and Sons Inc. 2020-07-26 2021-01 /pmc/articles/PMC7779275/ /pubmed/32530554 http://dx.doi.org/10.1111/jdi.13321 Text en © 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Kohsaka, Shun Takeda, Masayoshi Bodegård, Johan Thuresson, Marcus Kosiborod, Mikhail Yajima, Toshitaka Wittbrodt, Eric Fenici, Peter Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study |
title | Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study |
title_full | Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study |
title_fullStr | Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study |
title_full_unstemmed | Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study |
title_short | Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study |
title_sort | sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in japan: subanalyses of the cvd‐real 2 study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779275/ https://www.ncbi.nlm.nih.gov/pubmed/32530554 http://dx.doi.org/10.1111/jdi.13321 |
work_keys_str_mv | AT kohsakashun sodiumglucosecotransporter2inhibitorscomparedwithotherglucoseloweringdrugsinjapansubanalysesofthecvdreal2study AT takedamasayoshi sodiumglucosecotransporter2inhibitorscomparedwithotherglucoseloweringdrugsinjapansubanalysesofthecvdreal2study AT bodegardjohan sodiumglucosecotransporter2inhibitorscomparedwithotherglucoseloweringdrugsinjapansubanalysesofthecvdreal2study AT thuressonmarcus sodiumglucosecotransporter2inhibitorscomparedwithotherglucoseloweringdrugsinjapansubanalysesofthecvdreal2study AT kosiborodmikhail sodiumglucosecotransporter2inhibitorscomparedwithotherglucoseloweringdrugsinjapansubanalysesofthecvdreal2study AT yajimatoshitaka sodiumglucosecotransporter2inhibitorscomparedwithotherglucoseloweringdrugsinjapansubanalysesofthecvdreal2study AT wittbrodteric sodiumglucosecotransporter2inhibitorscomparedwithotherglucoseloweringdrugsinjapansubanalysesofthecvdreal2study AT fenicipeter sodiumglucosecotransporter2inhibitorscomparedwithotherglucoseloweringdrugsinjapansubanalysesofthecvdreal2study |